PKM and breast cancer: In the conditioned medium of human TECs pretreated with cisplatin or other nephrotoxic substances (such as cyclosporine A and HgCl2), the secretion of PKM2 increased, and this effect was not observed in liver and breast cancer cells, suggesting that PKM2 is specific to renal cells and can be used as an early marker of nephrotoxicity (94).